Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 132 pages

Showing 1 - 50


cns cancers

Erica H. Bell, PhD, on Low-Grade Gliomas: Subgroup Analysis of the NRG Oncology/RTOG 9802 Trial

Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy plus procarbazine/lomustine/vincristine in high-risk low-grade gliomas (Abstract 161).

cns cancers
colorectal cancer
gynecologic cancers
kidney cancer
lung cancer

FDA Approves Bevacizumab Biosimilar for Five Cancer Types

On June 28, the U.S. Food and Drug Administration (FDA) approved bevacizumab-bvzr (Zirabev), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell ...

cns cancers
lymphoma

Cytoreductive Surgery for Primary Central Nervous System Lymphoma

Through a systematic review of published studies, researchers report they have identified a distinct subtype of primary central nervous system (PCNS) lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed. These findings...

cns cancers
immunotherapy

2019 ASCO: Combination Therapy With SurVaxM in Newly Diagnosed Glioblastoma

Ahluwalia et al shared research results on SurVaxM at the 2019 ASCO Annual Meeting, reporting that combination therapy with the immunotherapy vaccine was more effective than standard therapy for nearly all patients with newly diagnosed glioblastoma in a phase II trial (Abstract 2016). SurVaxM...

cns cancers

2019 ASCO: Subgroups of Patients With Low-Grade Glioma May Benefit From PCV Chemotherapy Plus Radiotherapy

A recent, updated predictive analysis of the three World Health Organization (WHO)-defined molecular subgroups based on IDH mutation status and 1p/19q codeletion status represented in the high-risk treatment arms of a phase III trial found that both IDH-mutant subgroups may derive benefit ...

cns cancers

Manmeet S. Ahluwalia, MD, on Glioblastoma: Novel Cancer Vaccine With Standard Therapy

Manmeet S. Ahluwalia, MD, of the Taussig Center Institute, Cleveland Clinic, discusses phase II findings on the efficacy and immunogenicity of SurVaxM, a novel cancer vaccine targeting the tumor-specific antigen survivin in newly diagnosed glioblastoma (Abstract 2016).

cns cancers
solid tumors
leukemia
multiple myeloma
sarcoma

FDA Pipeline: Designations in Myeloma, Adenoid Cystic Carcinoma, and Kaposi Sarcoma, Plus ODAC Votes

This week, the U.S. Food and Drug Administration granted designations in relapsed or refractory multiple myeloma, adenoid cystic carcinoma, and Kaposi sarcoma; and the FDA’s Oncologic Drugs Advisory Committee (ODAC) held votes on treatments for tenosynovial giant cell tumor and acute...

cns cancers

ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?

A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...

cns cancers
leukemia
multiple myeloma

FDA Pipeline: Designations in Glioblastoma, Neurofibromatosis, Multiple Myeloma, and AML

This week, the U.S. Food and Drug Administration (FDA) granted designations for treatments for recurrent glioblastoma, neurofibromatosis type 1 and plexiform neurofibromas, multiple myeloma, and relapsed or refractory FLT3-ITD acute myeloid leukemia (AML). Fast Track Designation for Ad-RTS-hIL-12...

cns cancers

Does Postoperative Conformal Radiotherapy Improve Survival in Pediatric Patients With Ependymoma?

Treatment with conformal radiation therapy immediately following surgery in children with ependymoma may greatly improve survival. The findings were published by Merchant et al in the Journal of Clinical Oncology. “Historically, children under the age of 3 with ependymoma have a worse...

cns cancers
immunotherapy

Madhav V. Dhodapkar, MBBS, on Cancer Vaccines: Emerging Trends

Madhav V. Dhodapkar, MBBS, of Emory University, summarizes a session he co-chaired on emerging approaches for vaccines, personalized/neoantigen vaccines, and mutation-targeted immunotherapy for diffuse midline gliomas.

cns cancers

Higher Incidence of Brain and CNS Tumors Among People Living in Appalachia

A recent study published by Ostrom et al in the Journal of Neuro-Oncology showed that compared to the rest of the United States, the Appalachian region has a 5% higher incidence of malignant primary brain tumors and other central nervous system (CNS) tumors, a higher mortality rate due to ...

cns cancers

2018 ASTRO: Impact of MGMT Gene Expression on Overall Survival in Patients With Anaplastic Glioma

A phase III trial revealed that elevated MGMT gene expression is independently associated with worse overall survival for patients with anaplastic grade III gliomas. These findings were presented by Fleming et al at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) and...

cns cancers

Oncology Organizations Remember Senator John McCain

United States Senator from Arizona John McCain passed away on August 25 of the brain cancer glioblastoma multiforme (GBM). Numerous medical societies issued statements in light of his death, reprinted below. ASCO  ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, issued the following...

cns cancers
issues in oncology

Memory Issues in Children With Medulloblastoma Undergoing Radiation Therapy

Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of events they experienced after radiation than to remember pretreatment happenings, according to a Baylor University study comparing them to children with healthy brains. These...

cns cancers
lymphoma

Philip J. Bierman, MD, on DLBCL: Managing Patients at Risk of CNS Involvement and Systemic Disease

Philip J. Bierman, MD, of the University of Nebraska Medical Center, discusses how to identify and treat the 1% to 2% of patients with diffuse large B-cell lymphoma who have central nervous system involvement as well as systemic sites at the time of diagnosis.

cns cancers
issues in oncology

Pediatric CT Scans and Subsequent Malignancy Risk

A new study by Meulepas et al in the Journal of the National Cancer Institute suggests that computed tomography (CT) scans may increase the risk of brain tumors. The use of CT scans has increased dramatically over the past 2 decades. CT scans greatly improve diagnostic capabilities,...

cns cancers
immunotherapy

Treating Pediatric Glioma With Bevacizumab and Standard Treatment

Children with nonbrainstem high-grade glioma could benefit from potentially life-extending treatment if genetic testing was used to personalize therapy as it is in many adults, new research published by Mackay et al in Cancer Cell reported.  Scientists analyzed the DNA of children taking an...

cns cancers

Genetic Counseling and Testing for Patients With Medulloblastoma

Researchers have identified six genes that predispose carriers to develop medulloblastoma and have used the discovery to craft genetic counseling and screening guidelines. The study was published by Waszak et al in The Lancet Oncology. St. Jude Children’s Research Hospital,...

cns cancers

Does Treatment With Tumor-Treating Fields Plus Temozolomide Influence Quality of Life in Patients With Newly Diagnosed Glioblastoma?

A detailed quality-of-life analysis of the phase III EF-14 trial of tumor-treating fields (Optune) in combination with temozolomide for the treatment of newly diagnosed glioblastoma was published by Taphoorn et al in JAMA Oncology. This secondary endpoint analysis demonstrated that the...

cns cancers

FDA Grants Bevacizumab Full Approval in Recurrent Glioblastoma

On December 5, the U.S. Food and Drug Administration (FDA) granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. Bevacizumab was previously granted provisional approval in this setting under the FDA's ...

cns cancers

AACR-NCI-EORTC: Gene Therapy Shows Early Efficacy Against Recurrent Brain Cancer

More than a quarter of patients with recurrent high-grade glioma treated with the retroviral vector Toca 511 (vocimagene amiretrorepvec) combined with Toca FC (an extended-release formulation of fluorocytosine, a prodrug of fluorouracil [5-FU]) were alive more than 3 years after...

cns cancers
gynecologic cancers
kidney cancer
lung cancer
gastroesophageal cancer

FDA Approves First Biosimilar for the Treatment of Cancer

The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to...

cns cancers

Zika Virus Shows Oncolytic Activity Against Glioblastoma Stem Cells in Preclinical Trial

Although Zika virus causes devastating damage to the brains of developing fetuses, it someday may prove to be an effective treatment for glioblastoma. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine showed that...

cns cancers
survivorship

Study Maps Mutation That May Drive Meningioma Development in Childhood Cancer Survivors

Neuroscientists may have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumor, decades after their treatment with cranial radiation. The findings, published by Agnihotri et al in Nature Communications, show that...

cns cancers

Analysis Reveals Genomic Alterations, Oncogenes Driving Medulloblastoma Subtypes

The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75% of the brain tumors, including two new suspected cancer genes that were found exclusively in the least understood disease subgroups. The study from an international research...

cns cancers
issues in oncology

Study Demonstrates Potential for Artificial Intelligence and Whole-Genome Sequencing to Scale Access to Precision Medicine

In a study published by Wrzeszczynski et al in Neurology: Genetics, researchers at the New York Genome Center (NYGC), The Rockefeller University, and IBM illustrated the potential of IBM Watson for Genomics to analyze complex genomic data from state-of-the-art sequencing of whole genomes. The study ...

cns cancers

FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Gliomas

On June 6, the U.S. Food and Drug Administration (FDA) approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan), as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization [WHO] Grades III or IV) for preoperative imaging, as an adjunct for the...

cns cancers

Eric Jonasch, MD, on Von-Hippel Lindau Disease: Pazopanib Trial

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the...

cns cancers

AANS 2017: Seizure Outcome After Surgical Resection of Insular Glioma

Winner of the Journal of Neuro-Oncology Award sponsored by Kluwer Academic Publishers, Doris Du Wang, MD, PhD, a resident in the Department of Neurological Surgery at the University of California San Francisco (UCSF), presented her research on seizure outcome after surgical resection of insular...

cns cancers

AANS 2017: Genetic Underpinnings of Desmoplastic Infantile Ganglioglioma/Astrocytoma

Winner of the American Brain Tumor Association Young Investigator Award Anthony C. Wang, MD, a neurosurgeon at the University of California Los Angeles (UCLA) Mattel Children’s Hospital and the David Geffen School of Medicine at UCLA, presented his research findings on desmoplastic infantile...

cns cancers

Potential Therapeutic Target for Malignant Teratoid/Rhabdoid Tumors Identified in Preclinical Study

Using state-of-the-art gene-editing technology, scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have discovered a promising target to treat atypical teratoid/rhabdoid tumor, a highly aggressive and therapy-resistant brain tumor that mostly occurs in infants. They found...

cns cancers

AACR 2017: Addition of TTFields to Temozolomide Treatment Improves Survival for Patients With Glioblastoma

Patients with glioblastoma who wore a medical device that delivers alternating electrical fields in addition to being treated with the chemotherapeutic temozolomide had significantly improved median overall survival compared with those treated with temozolomide only, according to final results from ...

cns cancers

Key Gene Controlling Tumor Growth in Gliomas Pinpointed

Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings, published by Edwards et al in Nature Scientific Reports, could move physicians closer to their...

cns cancers

Study Finds No Evidence of Cytomegalovirus in Glioblastoma and Other High-Grade Gliomas

In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins said they have found no evidence of cytomegalovirus (CMV) infection and concluded that a link between the two diseases, as claimed by earlier reports, likely does not exist. A ...

cns cancers

Holger N. Lode, MD: Neuroblastoma Survival Update

Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)

cns cancers
sarcoma

Combination of Alisertib and HSV1716 Shows Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor and Neuroblastoma Models

Two investigational agents, the aurora A kinase inhibitor alisertib and a virus derived from HSV-1 (HSV1716), have shown antitumor efficacy in early clinical trials as monotherapies. A new study published by Currier et al in Oncotarget, however, demonstrates that the combined usage...

cns cancers

Precision Medicine Analysis of 203 Pediatric Brain Tumors May Advance Diagnosis and Treatment

Precision medicine has advanced to the point where it can now impact the care of a majority of children with brain tumors, a new study by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center suggests. In the largest clinical study to date of genetic abnormalities in...

cns cancers
gastrointestinal cancer

EORTC-NCI-AACR 2016: ‘Remarkable Antitumor Activity’ in Phase I Studies of PDGFRα and KIT Mutation Inhibitors

Two studies at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes provide instructions for making proteins that are part of a family of proteins called receptor...

cns cancers

Activation of WNT5A May Drive Glioblastoma Stem Cell Differentiation and Invasive Growth

Glioblastoma multiforme remains the most common and highly lethal brain cancer, known for its tendency to recur. Researchers at The University of Texas MD Anderson Cancer Center have identified a pathway by which cancer cells aggressively spread and grow in the brain, opening up new possibilities...

cns cancers

ASTRO 2016: Stereotactic Radiosurgery Decreases Rate of Postoperative Local Recurrence for Brain Metastases

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence, but shows no positive difference in terms of overall survival or distant brain metastases rates when compared to observation alone following surgical...

cns cancers

ASTRO 2016: Reduced Radiation Boost Volume Recommended for Average-Risk Pediatric Medulloblastoma, but Craniospinal Axis Dose Remains Unchanged

In the largest trial conducted for average-risk medulloblastoma, survival rates following reduced radiation therapy boost volumes were comparable to standard treatment volumes for the primary tumor site, but lower doses of craniospinal axis irradiation were associated with higher event rates and...

cns cancers

ASTRO 2016: Postoperative Stereotactic Radiosurgery: New Standard of Care for Patients With Resected Brain Metastases?

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline, and better quality of life, compared to whole-brain radiotherapy (WBRT), according to research presented at the 58th Annual ...

cns cancers

Effect of Radiosurgery Alone vs Radiosurgery Plus WBRT on Cognitive Function in Patients With Brain Metastases

Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study published by Brown et al in JAMA. The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery (SRS) alone, compared...

cns cancers

Analysis of Cerebrospinal Fluid for D-2-Hydroxyglutarate May Detect Malignant Brain Tumors Nonsurgically

When a brain tumor is suspected, its presence is usually confirmed by anatomic imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). But through imaging, not much about the tumor molecularly can be learned. Surgery and a biopsy are necessary to get a glimpse of the cancer...

cns cancers

Julie R. Park, MD, on Neuroblastoma: Results of a Children’s Oncology Group Study

Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cell as consolidation therapy for high-risk neuroblastoma (Abstract LBA3).

cns cancers

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).

cns cancers

ASCO 2016: Tandem Autologous Stem-Cell Transplant Improves Outcomes for Children With High-Risk Neuroblastoma

Historically, less than 50% of children with high-risk neuroblastoma live 5 or more years after diagnosis. A National Cancer Institute (NCI)-funded phase III trial performed by the Children’s Oncology Group found that adding a second autologous stem-cell transplant to standard therapy...

cns cancers

ASCO 2016: Temozolomide Chemotherapy Plus Short-Course Radiotherapy Improves Survival in Elderly Patients With Glioblastoma

A Canadian-led randomized phase III trial found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%. These data...

cns cancers

Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).

Advertisement

Advertisement



Advertisement